PMID- 35583827
OWN - NLM
STAT- MEDLINE
DCOM- 20230414
LR  - 20230414
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 149
IP  - 5
DP  - 2023 May
TI  - Detection of MET amplification by droplet digital PCR in peripheral blood samples 
      of non-small cell lung cancer.
PG  - 1667-1677
LID - 10.1007/s00432-022-04048-4 [doi]
AB  - PURPOSE: Mesenchymal-epithelial transition (MET) amplification is one of the 
      mechanisms accounting for the resistance of epidermal growth factor receptor 
      (EGFR) tyrosine kinase inhibitors (TKIs) in lung cancer patients, as well as the 
      poor prognosis. Fluorescence in situ hybridization (FISH) is the most widely used 
      method for MET amplification detection. However, it is inapplicable when tissue 
      samples were unavailable. Herein, we assessed the value of droplet digital PCR 
      (ddPCR) in MET copy number gain (CNG) detection in non-small cell lung cancer 
      (NSCLC) patients treated with EGFR-TKIs. MATERIALS AND METHODS: A total of 103 
      cancer tissues and the paired peripheral blood samples from NSCLC patients were 
      collected for MET CNG detection using ddPCR. In parallel, MET amplification in 
      tissue samples was verified by FISH. Also, the relationships between MET CNG and 
      EGFR T790M, as well as the EGFR-TKI resistance were also evaluated using 
      Chi-square or Fisher's exact tests. RESULT: The concordance rate of ddPCR and 
      FISH in detecting MET CNG in tissue samples was 100% (102/102), and it was 94.17% 
      (97/103) for ddPCR method in detecting the MET CNG among peripheral blood and 
      tissue samples. No statistical difference was observed between MET amplification 
      and EGFR T790M (p = 0.65), while MET amplification rate was significantly 
      increased in patients with resistance to third generations of EGFR-TKIs as 
      compared with patients with resistance to first/second EGFR-TKIs (p < 0.05). 
      CONCLUSIONS: ddPCR is an alternative method to detect MET CNG in both tissues and 
      peripheral blood samples, which is of worthy in clinical promotion.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Fan, Ying
AU  - Fan Y
AD  - State Key Laboratory of Genetic Engineering and MOE Engineering Research Center 
      of Gene Technology, School of Life Sciences, Fudan University, Shanghai, 200438, 
      Shanghai, China.
AD  - Shanghai Yuanqi Biomedical Technology Co., Ltd., Shanghai, 201403, China.
FAU - Sun, Rui
AU  - Sun R
AD  - Department of Molecular Pathology, Henan Cancer Hospital, The Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, 450003, China.
AD  - Henan Key Laboratory of Molecular Pathology, Zhengzhou, 450003, China.
FAU - Wang, Zhizhong
AU  - Wang Z
AD  - Department of Molecular Pathology, Henan Cancer Hospital, The Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, 450003, China.
AD  - Henan Key Laboratory of Molecular Pathology, Zhengzhou, 450003, China.
FAU - Zhang, Yuying
AU  - Zhang Y
AD  - Shanghai Yuanqi Biomedical Technology Co., Ltd., Shanghai, 201403, China.
FAU - Xiao, Xiao
AU  - Xiao X
AD  - Shanghai Yuanqi Biomedical Technology Co., Ltd., Shanghai, 201403, China.
FAU - Liu, Yizhe
AU  - Liu Y
AD  - Shanghai Yuanqi Biomedical Technology Co., Ltd., Shanghai, 201403, China.
FAU - Xin, Beibei
AU  - Xin B
AD  - Shanghai Yuanqi Biomedical Technology Co., Ltd., Shanghai, 201403, China.
FAU - Xiong, Hui
AU  - Xiong H
AD  - Shanghai Yuanqi Biomedical Technology Co., Ltd., Shanghai, 201403, China.
FAU - Lu, Daru
AU  - Lu D
AD  - State Key Laboratory of Genetic Engineering and MOE Engineering Research Center 
      of Gene Technology, School of Life Sciences, Fudan University, Shanghai, 200438, 
      Shanghai, China. drlu@fudan.edu.cn.
AD  - NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Key 
      Laboratory of Birth Defects and Reproductive Health, Chongqing Population and 
      Family Planning, Science and Technology Research Institute, Chongqing, 400014, 
      China. drlu@fudan.edu.cn.
FAU - Ma, Jie
AU  - Ma J
AUID- ORCID: 0000-0003-3516-9917
AD  - Department of Molecular Pathology, Henan Cancer Hospital, The Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, 450003, China. 
      majie_henanch@163.com.
AD  - Henan Key Laboratory of Molecular Pathology, Zhengzhou, 450003, China. 
      majie_henanch@163.com.
LA  - eng
GR  - 201300310400/Major public welfare projects in Henan Province Research and 
      development of new technologies for tumor liquid biopsy and immunotherapy./
PT  - Journal Article
DEP - 20220518
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - ErbB Receptors
MH  - In Situ Hybridization, Fluorescence
MH  - Mutation
MH  - Drug Resistance, Neoplasm/genetics
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Polymerase Chain Reaction/methods
OTO - NOTNLM
OT  - EGFR T790M
OT  - FISH
OT  - Liquid biopsy
OT  - MET amplification
OT  - NSCLC
OT  - ddPCR
EDAT- 2022/05/19 06:00
MHDA- 2023/04/14 06:42
CRDT- 2022/05/18 11:45
PHST- 2021/12/09 00:00 [received]
PHST- 2022/04/27 00:00 [accepted]
PHST- 2023/04/14 06:42 [medline]
PHST- 2022/05/19 06:00 [pubmed]
PHST- 2022/05/18 11:45 [entrez]
AID - 10.1007/s00432-022-04048-4 [pii]
AID - 10.1007/s00432-022-04048-4 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2023 May;149(5):1667-1677. doi: 
      10.1007/s00432-022-04048-4. Epub 2022 May 18.